Artiva Biotherapeutics (ARTV) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Artiva Biotherapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 7 insiders bought $109M and 5 sold $2.7M of ARTV stock on the open market, including a cluster buy that began Jul 10, 2026.
Get emailed when insiders cluster-buy stocks like ARTV
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ARTV insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $726K | 5 |
| Q3 2026 | $5.1M | 11 | $1.3M | 7 |
| Q2 2026 | $104M | 11 | $478K | 5 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | — | 0 | $194K | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 7 Artiva Biotherapeutics, Inc. insiders reported open-market purchases totaling $109M, while 5 insiders reported sales totaling $2.7M. The most recent cluster buy began on Jul 10, 2026, when 5 insiders bought a combined $4.7M. Among insiders with enough purchase history to measure, Peter Kolchinsky (Director) has the highest Insider Score at 99. 7 of 20 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ARTV earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 6, 2026 | +15.9% | Bought $5.1M (5) | -2.8%S&P +0.5% | -0.7% |
| May 8, 2026 | +6.7% | None | -15.3%S&P +1.1% | -30.0% |
| Mar 10, 2026 | +22.0% | None | +24.9%S&P -0.3% | -4.5% |
| Nov 12, 2025 | -28.8% | Sold $153K | -5.6%S&P -1.6% | -2.7% |
| Aug 6, 2025 | +20.8% | None | -14.3%S&P +0.7% | +36.7% |
| May 8, 2025 | -14.3% | None | -1.0%S&P +0.6% | +1.0% |
| Mar 24, 2025 | -16.3% | None | -6.6%S&P +2.0% | -38.6% |
| Nov 12, 2024 | +27.9% | None | -12.6%S&P -0.3% | -9.2% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 7SEC | Fred AslanCEO | Sell Plan | 23,4631,519,606 held (−2%) | $7.20 | $169K | -3.6% | — |
| Oct 6SEC | Fred AslanCEO | Sell | 61,6961,543,069 held (−4%) | $6.84 | $422K | +1.5% | — |
| Oct 6SEC | Christopher HoranChief Tech Operations Officer | Sell | 10,340312,744 held (−3%) | $6.84 | $71K | +1.5% | — |
| Oct 6SEC | Jennifer BushCOO, General Counsel | Sell | 8,370366,159 held (−2%) | $6.84 | $57K | +1.5% | — |
| Oct 6SEC | Subhashis BanerjeeChief Medical Officer | Sell | 1,099169,848 held (−1%) | $6.84 | $8K | +1.5% | — |
| Sep 9SEC | Fred AslanCEO | Sell Plan | 23,4291,449,765 held (−2%) | $10.92 | $256K | -36.4% | — |
| Sep 4SEC | Fred AslanCEO | Sell | 61,8881,473,194 held (−4%) | $11.16 | $691K | -37.8% | — |
| Sep 4SEC | Christopher HoranChief Tech Operations Officer | Sell | 10,366283,084 held (−4%) | $11.16 | $116K | -37.8% | — |
| Sep 4SEC | Jennifer BushCOO, General Counsel | Sell | 8,391329,529 held (−2%) | $11.16 | $94K | -37.8% | — |
| Sep 4SEC | Subhashis BanerjeeChief Medical Officer | Sell | 1,100140,947 held (−1%) | $11.16 | $12K | -37.8% | — |
| Aug 31SEC | Subhashis BanerjeeChief Medical Officer | Sell Plan | 8,222142,047 held (−5%) | $12.01 | $99K | -42.2% | — |
| Aug 19SEC | Subhashis BanerjeeChief Medical Officer | Sell Plan | 429144,963 held (−0%) | $12.00 | $5K | -42.2% | — |
| Jul 31SEC | Ra Capital Healthcare Fund LpDirector | Buy | 24,94417,329,570 held (+0%) | $9.93 | $248K | -30.1% | 98 |
| Jul 31SEC | Ra Capital Healthcare Fund LpDirector | Buy | 20,82417,304,626 held (+0%) | $9.99 | $208K | -30.5% | 98 |
| Jul 28SEC | Ra Capital Nexus Fund Iii, L.P.Director | Buy | 41,31917,283,802 held (+0%) | $9.99 | $413K | -30.5% | 85 |
| Jul 23SEC | Peter KolchinskyDirector | Buy | 120,58217,098,479 held (+1%) | $9.55 | $1.2M | -27.3% | 99 |
| Jul 23SEC | Peter KolchinskyDirector | Buy | 84,12417,182,603 held (+0%) | $9.93 | $835K | -30.1% | 99 |
| Jul 23SEC | Peter KolchinskyDirector | Buy | 59,88017,242,483 held (+0%) | $9.96 | $596K | -30.3% | 99 |
| Jul 23SEC | Ra Capital Nexus Fund, L.P.Director | Buy | 6,52216,817,543 held (+0%) | $8.94 | $58K | -22.4% | — |
| Jul 20SEC | Ra Capital Healthcare Fund LpDirector | Buy | 152,47216,970,045 held (+1%) | $8.93 | $1.4M | -22.3% | 98 |
| Jul 20SEC | Ra Capital Healthcare Fund LpDirector | Buy | 7,88216,977,927 held (+0%) | $8.95 | $71K | -22.5% | 98 |
| Jul 14SEC | Rajeev M. ShahDirector | Buy | 15,10216,811,021 held (+0%) | $8.97 | $135K | -22.6% | 90 |
| Jul 14SEC | Rajeev M. ShahDirector | Buy | 6,55216,817,573 held (+0%) | $8.94 | $59K | -22.4% | 90 |
| Jun 29SEC | Ra Capital Management, L.P.Director | Buy | 31,00016,794,043 held (+0%) | $8.88 | $275K | -21.8% | 92 |
| Jun 29SEC | Ra Capital Management, L.P.Director | Buy | 1,87616,795,919 held (+0%) | $8.98 | $17K | -22.7% | 92 |
| Jun 16SEC | Peter KolchinskyDirector | Buy | 391,01916,622,736 held (+2%) | $8.57 | $3.4M | -19.0% | 99 |
| Jun 16SEC | Peter KolchinskyDirector | Buy | 124,89316,763,043 held (+1%) | $8.89 | $1.1M | -21.9% | 99 |
| Jun 16SEC | Peter KolchinskyDirector | Buy | 15,41416,638,150 held (+0%) | $8.99 | $139K | -22.8% | 99 |
| Jun 11SEC | Ra Capital Nexus Fund, L.P.Director | Buy | 548,58016,231,717 held (+3%) | $7.91 | $4.3M | -12.3% | — |
| Jun 11SEC | Ra Capital Nexus Fund, L.P.Director | Buy | 479,03915,683,034 held (+3%) | $6.91 | $3.3M | +0.4% | — |
| Jun 11SEC | Ra Capital Nexus Fund, L.P.Director | Buy | 10315,683,137 held (+0%) | $7.00 | $721 | -0.9% | — |
| May 28SEC | Gc Corp.10% Owner | Buy | 1,085,0694,391,969 held (+33%) | $11.52 | $12.5M | -39.8% | — |
| May 28SEC | Gc Corp.10% Owner | Buy | 347,2221,607,734 held (+28%) | $11.52 | $4.0M | -39.8% | — |
| May 19SEC | Fred AslanCEO | Sell | 27,1161,535,082 held (−2%) | $9.01 | $244K | -23.0% | — |
| May 19SEC | Jennifer BushCOO, General Counsel | Sell | 8,790337,920 held (−3%) | $9.01 | $79K | -23.0% | — |
| May 19SEC | Subhashis BanerjeeChief Medical Officer | Sell | 7,037144,963 held (−5%) | $9.01 | $63K | -23.0% | — |
| May 19SEC | Christopher HoranChief Tech Operations Officer | Sell | 7,002293,450 held (−2%) | $9.01 | $63K | -23.0% | — |
| May 19SEC | Heather RaymonSvp, Research And Development | Sell | 3,095148,228 held (−2%) | $9.01 | $28K | -23.0% | — |
| May 13SEC | Ra Capital Nexus Fund Iii, L.P.Director | Buy | 6,510,41615,203,995 held (+75%) | $11.52 | $75.0M | -39.8% | 85 |
| Dec 15SEC | Fred AslanCEO, President | Sell Plan | 3,1871,209,948 held (−0%) | $6.00 | $19K | +15.7% | — |
| Nov 17SEC | Fred AslanCEO, President | Sell Plan | 6,375343,999 held (−2%) | $3.38 | $22K | +105.3% | — |
| Oct 17SEC | Fred AslanCEO, President | Sell Plan | 25,500356,721 held (−7%) | $6.00 | $153K | +15.7% | — |
Insiders at Artiva Biotherapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Ra Capital Nexus Fund Iii, L.P.Director | $75.4M | — | Jul 28, 2026 | 85 |
| Gc Corp.10% Owner | $16.5M | — | May 28, 2026 | — |
| Ra Capital Nexus Fund, L.P.Director | $7.7M | — | Jul 23, 2026 | — |
| Peter KolchinskyDirector | $7.2M | — | Jul 23, 2026 | 99 |
| Ra Capital Healthcare Fund LpDirector | $1.9M | — | Jul 31, 2026 | 98 |
| Fred AslanCEO | — | $2.0M | Oct 7, 2026 | — |
| Ra Capital Management, L.P.Director | $292K | — | Jun 29, 2026 | 92 |
| Rajeev M. ShahDirector | $194K | — | Jul 14, 2026 | 90 |
| Christopher HoranChief Tech Operations Officer | — | $249K | Oct 6, 2026 | — |
| Jennifer BushCOO, General Counsel | — | $230K | Oct 6, 2026 | — |
| Subhashis BanerjeeChief Medical Officer | — | $187K | Oct 6, 2026 | — |
| Heather RaymonSvp, Research And Development | — | $28K | May 19, 2026 | — |
ARTV stock: common questions
Are Artiva Biotherapeutics, Inc. insiders buying ARTV stock?
In the past 12 months, 7 insiders reported open-market purchases of ARTV worth $109M. The latest was Director Ra Capital Healthcare Fund Lp bought $248K of ARTV at $9.93.
Are Artiva Biotherapeutics, Inc. insiders selling ARTV stock?
5 insiders reported sales worth $2.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ARTV's 52-week range?
Over the past year ARTV has traded between $2.74 and $13.39. It last closed at $6.94 on Oct 9, 2026.